Allelica have a Polygenic Risk Score product as well, as much as...

Allelica have a Polygenic Risk Score product as well, as much as GTG needs sales, they also need PRS to become mainstream for diagnosis. If Allelica succeed, who have investments by Merck, then other pharma and healthcare companies will be scrambling for a platform and will buy GTG. Waiting for GTG to develop the market themselves will probably take a while unless they are lucky in picking up an interested insurer or investment from pharma, but they probably lack the skills and resources as a company to achieve this, their benefit is more first mover advantage (which is starting to slip).
The Sonic investment into Microba is similar, Microba invested in building a library of microbes to characterise the human gut, they have the scientific pedigree and a developed product and so are a more advanced company, but Sonic recognised that understanding a persons microbiome has a benefit in order to diagnose disease (or promote wellness) the same way that PTS genetic testing by GTG can do. Its a confirmation that genomics are the way of the future and possibly an opportunity for GTG to build value/opportunity.....if they can. Hopefully GTG promote this angle rather than genetic testing of racehorses in India...........